Charles Schwab’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-517,263
| Closed | -$10.4M | – | 3605 |
|
|
2021
Q3 | $10.4M | Buy |
517,263
+17,340
| +3% | +$479K | ﹤0.01% | 1983 |
|
|
2021
Q2 | $18.7M | Sell |
499,923
-40,446
| -7% | -$1.24M | 0.01% | 1633 |
|
|
2021
Q1 | $13.8M | Buy |
540,369
+20,862
| +4% | +$533K | 0.01% | 1771 |
|
|
2020
Q4 | $11.4M | Buy |
519,507
+10,269
| +2% | +$226K | ﹤0.01% | 1784 |
|
|
2020
Q3 | $9.16M | Buy |
509,238
+34,566
| +7% | +$716K | ﹤0.01% | 1756 |
|
|
2020
Q2 | $12.1M | Buy |
474,672
+120,396
| +34% | +$2.59M | 0.01% | 1523 |
|
|
2020
Q1 | $6.51M | Buy |
354,276
+31,381
| +10% | +$610K | ﹤0.01% | 1702 |
|
|
2019
Q4 | $7.11M | Sell |
322,895
-25,930
| -7% | -$522K | ﹤0.01% | 1841 |
|
|
2019
Q3 | $5.01M | Buy |
348,825
+46,488
| +15% | +$664K | ﹤0.01% | 1957 |
|
|
2019
Q2 | $4.76M | Buy |
302,337
+1,881
| +0.6% | +$25.6K | ﹤0.01% | 1994 |
|
|
2019
Q1 | $4.4M | Buy |
300,456
+17,489
| +6% | +$201K | ﹤0.01% | 2031 |
|
|
2018
Q4 | $3.02M | Buy |
282,967
+53,037
| +23% | +$698K | ﹤0.01% | 2162 |
|
|
2018
Q3 | $3.51M | Buy |
229,930
+140,430
| +157% | +$2.04M | ﹤0.01% | 2228 |
|
|
2018
Q2 | $1.1M | Buy |
+89,500
| New | +$1.12M | ﹤0.01% | 2562 |
|
|
2016
Q2 | – | Sell |
-21,814
| Closed | -$117K | – | 3153 |
|
|
2016
Q1 | $117K | Hold |
21,814
| – | – | ﹤0.01% | 2974 |
|
|
2015
Q4 | $259K | Hold |
21,814
| – | – | ﹤0.01% | 2907 |
|
|
2015
Q3 | $180K | Hold |
21,814
| – | – | ﹤0.01% | 2975 |
|
|
2015
Q2 | $305K | Buy |
+21,814
| New | +$400K | ﹤0.01% | 2873 |
|
|
2014
Q3 | – | Sell |
-10,528
| Closed | -$238K | – | 3083 |
|
|
2014
Q2 | $238K | Buy |
+10,528
| New | +$191K | ﹤0.01% | 2947 |
|
Other funds holding DRNA
Charles Schwab's DRNA Position: Q4 2021 in Review
Charles Schwab sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 517,263 shares — an estimated $10.4M sold.
Charles Schwab first reported a position in DRNA in Q2 2014 and held it in 19 quarters. The position peaked at $18.7M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Charles Schwab reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Charles Schwab sold 517,263 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $10.4M.
- Charles Schwab first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 19 quarters.
- Charles Schwab's Dicerna Pharmaceuticals, Inc. position peaked at $18.7M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Charles Schwab's 13F filing for Q4 2021, filed 11 Feb 2022.